<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Sept. 21, 2018 (HealthDay News) — Vitamin D deficiency is independently associated with subclinical interstitial lung disease (ILD) and its progression, according to a study recently published in the Journal of Nutrition<\/i>.<\/p>\n
Samuel M. Kim, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues used data from 6,302 participants in the Multi-Ethnic Study of Atherosclerosis who had baseline serum 25-hydroxyvitamin D (25[OH]D) concentrations and computed tomography imaging partial lung fields spanning over 10 years.<\/p>\n
The researchers found that 33 percent of participants had replete (\u226530 ng\/mL), 35 percent intermediate (20 to <30 ng\/mL), and 32 percent deficient (<20 ng\/mL) 25(OH)D concentrations. Participants with 25(OH)D deficiency had greater adjusted high-attenuation area volume at baseline and increased progression over a median of 4.3 years of follow-up (P < 0.05), compared to participants with replete levels. There was also an association between 25(OH)D deficiency and increased prevalence of interstitial lung abnormalities 10 years later (odds ratio, 1.5).<\/p>\n
“Vitamin D deficiency is independently associated with subclinical ILD and its progression, based on both increased high-attenuation areas and interstitial lung abnormalities, in a community-based population,” the authors write. “Further studies are needed to examine whether vitamin D repletion can prevent ILD or slow its progression.”<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n